Scarica l'app Stockscreener
1.56
0.64%
-0.01
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GANX Giù?
Forum
Previsione
Precedente Chiudi:
$1.57
Aprire:
$1.55
Volume 24 ore:
148.26K
Relative Volume:
0.48
Capitalizzazione di mercato:
$41.38M
Reddito:
$210.70K
Utile/perdita netta:
$-21.37M
Rapporto P/E:
-0.8571
EPS:
-1.82
Flusso di cassa netto:
$-21.10M
1 W Prestazione:
-4.29%
1M Prestazione:
-6.02%
6M Prestazione:
+20.00%
1 anno Prestazione:
-36.07%
Intervallo 1D:
$1.50
$1.70
Intervallo di 1 settimana:
$1.50
$1.73
Portata 52W:
$0.89
$5.33
Gain Therapeutics Inc Stock (GANX) Company Profile
Nome
Gain Therapeutics Inc
Settore
Industria
Telefono
(301) 500-1556
Indirizzo
4800 HAMPDEN LANE, BETHESDA
Confronta GANX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
1.56 | 41.38M | 210.70K | -21.37M | -21.10M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-06 | Iniziato | ROTH MKM | Buy |
| 2024-08-14 | Ripresa | Oppenheimer | Outperform |
| 2021-04-12 | Iniziato | BTIG Research | Buy |
| 2021-04-12 | Iniziato | Oppenheimer | Outperform |
Gain Therapeutics Inc Borsa (GANX) Ultime notizie
Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know - MSN
Institutional investors may overlook Regulus Therapeutics Inc.'s (NASDAQ:RGLS) recent US$12m market cap drop as long-term gains remain positive - Simply Wall St
vTv Therapeutics (NASDAQ:VTVT) Stock Quotes, Forecast and News Summary - Benzinga
Gain Therapeutics' SWOT analysis: protein misfolding stock faces pivotal phase - Investing.com India
Quince Therapeutics, Inc. (NASDAQ:QNCX) Sees Large Increase in Short Interest - MarketBeat
Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews
Stock market news: Wintest surges 26.25%, Smaregi drops 16.74%, D. Western Therapeutics gains 25.96% in volatile midday trading - Business Upturn
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Short Interest Update - MarketBeat
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Sees Significant Increase in Short Interest - MarketBeat
NCATS Helped Develop a Gene Therapy for a Rare Brain Disorder - NCBI
Crude Oil Gains Over 1%; RH Shares Jump On Strong Forecast - Benzinga
Baxter Stock May Gain Following Five New Injectable Product Launches - Yahoo Finance
Gain Therapeutics To Present At Biotech Showcase 2025 - The Manila Times
Oruka Therapeutics, Inc. (NASDAQ:ORKA) institutional investors have had a good week as stock gains 15% - Yahoo Finance
Design Therapeutics Gains 11%, Insider Trades Reap Benefit - Simply Wall St
Biotech's Parkinson's Drug Could Be Worth US$4B, Analyst Says - Streetwise Reports
New NCCN Guidelines Boost Myriad Genetics' Prolaris: Stock to Gain? - Yahoo Finance
Beam Therapeutics Unveils New Safety, Efficacy Data From Sickle Cell Disease Candidate, Stock Gains - Yahoo Finance
Roth Mkm Begins Coverage on Gain Therapeutics (NASDAQ:GANX) - Defense World
Gain Therapeutics (NASDAQ:GANX) Upgraded at Roth Capital - Defense World
GANX shares initiated with buy rating on preclinical trials By Investing.com - Investing.com Canada
Roth MKM Initiates Coverage of Gain Therapeutics (GANX) with Buy Recommendation - MSN
GANX shares initiated with buy rating on preclinical trials - Investing.com
Gain Therapeutics' SWOT analysis: protein misfolding drug developer's stock outlook - Investing.com Canada
TMO Stock to Gain From the New Additions to CTS Portfolio of Products - Yahoo Finance
Dow Gains 250 Points; Salesforce Shares Jump After Q3 Results - Benzinga
Health Care Down, But Near All-Time Highs, as Biotech Firms Gain -- Health Care Roundup - Marketscreener.com
PTC Therapeutics Stock Eyes Further Rally After Price-Target Hikes On Huntington’s Therapy Deal With Novartis: Retail Buzz Grows - MSN
2024's 10 Best-Performing Stocks | Investing - U.S News & World Report Money
Gene Therapy Explosion Forces Employer Coverage to Get Creative - Bloomberg Law
S&P 500, Dow close at record highs on tech gains - Yahoo Finance
Rakovina Therapeutics Announces Increase in Private Placement Offering to $2.5 Million - Yahoo Finance
The 3.8% return this week takes United Therapeutics' (NASDAQ:UTHR) shareholders five-year gains to 314% - Yahoo Finance
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Increase in Short Interest - MarketBeat
HC Wainwright Lifts Earnings Estimates for Gain Therapeutics - Defense World
HC Wainwright Reaffirms “Buy” Rating for Gain Therapeutics (NASDAQ:GANX) - Defense World
Poseida Therapeutics, Inc. (PSTX) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Stock market today: Poseida Therapeutics +224.30%, Primega Group Holdings +98.77% among the top gainers in early trading - Business Upturn
BSX Stock Set to Gain From Agreement to Acquire Intera Oncology - Yahoo Finance
Eli Lilly, Novo Nordisk Stocks Gain as Biden Moves to Expand Coverage of Weight-Loss Drugs - Yahoo Finance
Gain Therapeutics shares hold Buy rating; H.C. Wainwright optimistic on GT-02287 clinical data - Investing.com India
FY2024 Earnings Forecast for GANX Issued By Chardan Capital - Defense World
Drug developer stocks slide further in fall, despite gains from Exelixis and Xencor - BioWorld Online
FATE Presents Encourgaing Data From Lupus Study, Stock Gains - Nasdaq
Stock Market News: Aclaris Therapeutics gains over 55% while Exicure increases almost 31% during mid day trading - Business Upturn
Stock market news: Renewable Japan jumps nearly 69% by mid-day, D. Western Therapeutics and Agile Media Network post strong gains - Business Upturn
Gain Therapeutics Advances Parkinson’s Therapy Development - TipRanks
Stock market today: Fate Therapeutics gains 70.79% whereas SiNtx Technologies rose by 38.73% in early trading - Business Upturn
Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Up 15.1% in October - Defense World
Chesapeake Granite Wash Trust (OTCMKTS:CHKR) Sees Large Increase in Short Interest - Defense World
PDS Biotechnology’s (PDSB) Buy Rating Reiterated at HC Wainwright - Defense World
Gain Therapeutics Inc Azioni (GANX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Gain Therapeutics Inc Azioni (GANX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Islam Khalid | Executive Chairman |
Aug 09 '24 |
Buy |
1.00 |
50,000 |
49,940 |
50,000 |
| RICHMAN ERIC I | Director |
Jul 01 '24 |
Buy |
1.22 |
17,000 |
20,670 |
289,629 |
| Riley Jeffrey Scott | Director |
Mar 28 '24 |
Buy |
3.86 |
30,000 |
115,770 |
30,000 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):